Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 300Fluorouracil 273Gemcitabine 238Bevacizumab 235Leucovorin 212Capecitabine 207pembrolizumab 201Irinotecan 159Nivolumab 158Cisplatin 151Specimen Handling 143Magnetic Resonance Spectroscopy 129130-nm albumin-bound paclitaxel 118Paclitaxel 109durvalumab 106Cetuximab 104Radiotherapy 99Drug Therapy 94atezolizumab 93Biopsy 92tislelizumab 81Albumin-Bound Paclitaxel 81Taxes 75lenvatinib 67Folfox protocol 67Carboplatin 66regorafenib 61Blood Specimen Collection 60sintilimab 54Ipilimumab 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
bavituximab × Gastrointestinal × 1 year × Clear all
NCT03519997 2026-02-11

A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

University of Texas Southwestern Medical Center

Phase 2 Active not recruiting
35 enrolled 10 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡